The subset of NSCLC cases with strongly PD‐L1‐positive neoplasms is the primary driver of clinical benefit from anti‐PD‐1 monotherapy (Pembrolizumab) in the whole research population.20 This evidence concerns the gene CD274 and non-small cell lung carcinoma.